Compendium of the most significant studies with reference to properties, intake, effects.

Treister NS, Woo SB. Topical n-docosanol for management of recurrent herpes labialis. Expert Opin Pharmacother. 2010 Apr;11(5):853-60. doi: 10.1517/14656561003691847.

Abstract

Importance of the field: Recurrent herpes labialis (RHL) is a significant disorder with social and health consequences that affects upwards of 20 - 40% of the adult population. Docosanol is the only FDA-approved topical agent that is available over the counter for management of RHL. Its mechanism of action is unique compared with other available antiviral agents.

Areas covered in this review: The authors conducted a comprehensive search of the published preclinical and clinical literature on topical docosanol for RHL. All of the published literature relating to docosanol and its use for the management of recurrent herpes labialis was reviewed, from the first report of docosanol to 31 January 2010.

What the reader will gain: The objective of this review was to summarize and critically evaluate the available literature with respect to topical docosanol's mechanism, safety and efficacy in the management of RHL.

Take home message: Ten percent docosanol cream is a safe and effective topical treatment for the management of RHL in immunocompetent adults, with essentially equivalent efficacy compared with other available prescription topical antiviral agents. Owing to its unique mechanism of action, there is little to no risk of developing resistance.

Lakshmi SA, Bhaskar JP, Krishnan V, Sethupathy S, Pandipriya S, Aruni W, Pandian SK. Inhibition of biofilm and biofilm-associated virulence factor production in methicillin-resistant Staphylococcus aureus by docosanol. J Biotechnol. 2020 Jun 20;317:59-69. doi: 10.1016/j.jbiotec.2020.04.014

.Abstract

Antimicrobial resistance is a major public health concern in infection control. Hence, a multi-pronged approach is necessary to curb the severity of infections. The present study entails the identification of docosanol (fatty alcohol) from Streptomyces as a novel antibiofilm agent which can target the virulence factors of MRSA. Results showed that docosanol as a potent antibiofilm agent and found to inhibit several virulence factors of MRSA. The antibiofilm efficacy of docosanol analyzed through light and scanning electron microscopy showed a significant reduction in adherent cells. Moreover, analysis of three-dimensional structure of biofilm matrix by confocal laser scanning microscope demonstrated effective antibiofilm potential of docosanol. In addition, docosanol reduced the survival rate of MRSA in healthy human blood and enhanced the neutrophil-mediated killing by interfering with hemolysin production. RT-qPCR analysis revealed the down regulation of several virulence genes, possibly by affecting the expression of the accessory gene regulator (agr) system and transcriptional regulator sarA. These findings suggest that docosanol could effectively reduce the biofilm phenotype and virulence production, and thus becomes a promising candidate to treat MRSA infections.

Iglesias G, Hlywka JJ, Berg JE, Khalil MH, Pope LE, Tamarkin D. The toxicity of behenyl alcohol. II. Reproduction studies in rats and rabbits. Regul Toxicol Pharmacol. 2002 Aug;36(1):80-5. doi: 10.1006/rtph.2002.1566.

Abstract

Behenyl alcohol is a saturated 22-carbon, long-chain aliphatic alcohol, which has potential for use in foods as an oil-structuring and -solidifying agent in fats. Previously completed studies with behenyl alcohol indicated an absence of mutagenic or genotoxic potential. In addition, subchronic toxicity studies in rats and dogs reported no adverse effects following gross and histopathological examinations. Compound-related effects were limited to the observation of pale feces in dogs treated with high doses of behenyl alcohol, and were attributable to unabsorbed behenyl alcohol. The reproductive effects of behenyl alcohol were investigated in a fertility and reproduction study, and an embryonic development study in rats and rabbits, respectively. No evidence of maternal or fetal toxicity was observed in either study. Behenyl alcohol demonstrated no effects on the fertility or reproduction of rats dosed up to 1000 mg/kg body weight. Similarly, behenyl alcohol had no reproductive effects on rabbits treated with doses up to 2000 mg/kg body weight. The observation of pale feces was the only compound-related effect reported, limited to rabbits treated with 2000 mg behenyl alcohol/kg body weight. Based on these findings, there is no evidence to suggest that behenyl alcohol is teratogenic or embryotoxic.